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Abstract: Five percent lidocaine medicated plaster has been proven efficacious for the symp-
tomatic relief of neuropathic pain in diverse pain conditions which might be attributed to a 
common localized symptomatology in these indications, possibly with common predictors 
of treatment success. To discuss potential symptoms and other factors predicting response to 
treatment with lidocaine plaster for the indications of low back pain with neuropathic com-
ponents and neuropathic pain after surgical and nonsurgical trauma, 44 pain specialists from 
17   countries attended a two-day conference meeting in December 2009. Discussions were based 
on the retrospective analysis of case reports (sent in by participants in the four weeks prior to 
the meeting) and the practical experience of the participants. The results indicate some predic-
tors for success with 5% lidocaine medicated plaster for the two indications. Localized pain, 
hyperalgesia and/or allodynia, and other positive sensory symptoms, such as dysesthesia, were 
considered positive predictors, whereas widespread pain and negative sensory symptoms were 
regarded as   negative predictors. Paresthesia, diagnosis, and site of pain were considered to be of 
no predictive value. Common symptomatology with other neurologic pathologies suggests that 
treatment of localized neuropathic pain symptoms with the plaster can be considered across 
different neuropathic pain indications.
Keywords: lidocaine plaster, low back pain, surgical and nonsurgical trauma pain, neuropathic 
pain, case report
Background
Five percent lidocaine medicated plaster (Versatis®; Grünenthal GmbH, Aachen, 
Germany) is a topical analgesic which is recommended as first-line therapy for the 
treatment of localized, peripheral, neuropathic pain.1 Its mechanism of action is not 
fully known, but it is assumed to block sodium channels associated with peripheral 
nerve endings, thereby reducing ectopic nociceptive pain signal transmission.2 The 
compound has been proven effective and well tolerated in the treatment of neuro-
pathic pain in patients with postherpetic neuralgia3–7 and diabetic polyneuropathy.3,4,8 
Although 5% lidocaine medicated plaster is currently only licensed for the 
symptomatic relief of neuropathic pain associated with previous herpes zoster 
infection (postherpetic neuralgia), it has been successfully used in patients with other 
neuropathic pain states, such as painful idiopathic distal sensory polyneuropathies,9 
entrapment neuropathies,10 and   postoperative/post-traumatic neuropathic chronic 
cutaneous pain (PNCCP).11,12Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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Lidocaine plaster also showed promise in the treatment of 
chronic low back pain. In two large uncontrolled, open-label 
studies including patients with moderate-to-severe low back 
pain, treatment with lidocaine plaster for six weeks signifi-
cantly reduced the intensity of pain and pain interference with 
quality of life.13,14 The addition of the lidocaine plaster to the 
analgesic regimen in chronic low back pain was beneficial 
in a case series of four patients.15
Low back pain and PNCCP frequently have complex 
underlying pathologies. The origin of chronic low back 
pain is controversially discussed. Amongst other conditions, 
such as inflammatory back pain,16 it is often attributed to 
degenerative changes in the spine which produce a syn-
drome of varying combinations of axial and limb pain.17 
The affected spinal structures may include muscle, nerve, 
vertebrae, thoracolumbar fascia, ligaments, facet joints, 
sacroiliac joints, and discs. Spinal degeneration proceeds 
from stability to instability and back to stability.18 Instabil-
ity is caused by disc dysfunction, tearing, or herniation and 
restabilization by bony overgrowth of the vertebral end plates 
and hypertrophy of the facets to compensate for the altered 
biomechanical loading.18,19 Peak incidences of lumbar and 
radicular pain are reached during the “instability phase”.18,20 
Compensatory bone growth results in progressive central 
canal and foraminal stenosis, leading to neural compression 
and vascular symptoms.20 Both nociceptive and neuropathic 
pain-generating mechanisms are thought to be involved in 
low back pain.21 For instance, radicular pain is most com-
monly caused by disc herniation, but the inflammation of 
the affected nerve seems to be the critical pathophysiologic 
process.22 As in other neuropathic pain conditions, peripheral 
and central mechanisms are involved in the pathogenesis of 
(chronic) low back pain.21 The present manuscript focuses on 
low back pain cases considered by their treating physicians 
to have a definite neuropathic component.
Chronic post-traumatic pain persisting in the location of 
surgical intervention beyond the usual course of natural heal-
ing is common, and has been reported after different types 
of surgery, eg, amputation, mastectomy, cardiac surgery, 
hernia repair, and thoracotomy.23 It is often due to partial 
or complete nerve lesions and subsequent development of 
a focal peripheral neuropathy.11 Allodynia or hyperalgesia 
are frequently observed sensory phenomena if part of the 
nervous structure is retained (partial lesion) and “overreacts” 
by, eg, upregulating sodium channels.24
The effectiveness of lidocaine plaster in such diverse 
neuropathic pain conditions might be attributed to a 
  common localized symptomatology in these patients, 
possibly with common predictors of treatment success. In 
view of the fact that generally satisfactory pain relief is 
experienced by #50% of patients in randomized clinical 
trials assessing efficacious neuropathic pain medications 
(with frequent side effects),25 outcome predictors for a given 
treatment may prove useful in order to save patients in pain 
from a potentially frustrating “trial and error” period and to 
find a successful treatment faster, and also be useful from a 
cost-effectiveness point of view. Two previous conference 
meetings of pain specialists in Athens, Greece (2007) and 
Berlin, Germany (2008) had focused on potential outcome 
predictors for the indications of diabetic polyneuropathy, 
complex regional pain syndrome, low back pain with neu-
ropathic components (nLBP), and PNCCP. The results of 
these two meetings have not been published. At those meet-
ings, localized hyperalgesia, allodynia, and a combination 
of positive and negative symptoms were seen as positive 
predictors for treatment success with lidocaine plaster in 
PNCCP, whereas deep pain, numbness, and cold allodynia 
were discussed as potential negative predictors in such con-
ditions. For low back pain, the specialists summarized their 
experiences of successful treatment with lidocaine plaster 
as follows: “For localized myofascial pain with tenderness 
to touch, with or without positive signs like allodynia and 
hyperalgesia, excluding radiating and radicular pain and 
with a neuropathic component”. It was, however, generally 
agreed that further discussions and a definition of predictors 
for the two indications nLBP and PNCCP on the basis of 
case reports was warranted. For this purpose, case reports 
were collected and analyzed at an additional two-day meet-
ing in Vienna, Austria in December 2009. The main results 
of this meeting are presented in this paper.
Meeting details
Pain practitioners experienced in the treatment of nLBP or 
PNCCP with 5% lidocaine medicated plaster were invited to 
a two-day meeting facilitated by Grünenthal GmbH to discuss 
potential symptoms and other baseline factors predicting 
response to treatment with lidocaine plaster. The discussions 
were based on the retrospective analysis of case reports and 
the practical experience of the participants. Forty-four pain 
specialists from 17 countries participated in this meeting. Two 
discussion groups for each clinical indication were formed, 
each moderated by one of the four authors of this paper.
Four weeks prior to the meeting, all participants were 
asked to contribute case reports for nLBP and/or PNCCP. Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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The time frame was felt appropriate for the retrospective 
collection of data but was insufficient for starting treatment 
de novo in view of the request (which was not permitted). 
Practitioners provided information about their cases using a 
standardized form documenting the following:
•	 Demographic data
•	 Primary diagnosis (pain indication/cause of pain)
•	 Other relevant diagnoses
•	 Localization of pain symptoms
•	 Duration and intensity of pain prior to initiation of treat-
ment with lidocaine plaster
•	 Physical examination and diagnostic tests
•	 Presence of clinical symptoms of pain (hyperalgesia, 
severity of allodynia, stabbing pain, burning pain, shoot-
ing pain, other symptoms)
•	 Prior and concomitant medication
•	 Start of therapy with lidocaine plaster
•	 Application frequency, number of plasters and duration 
of treatment
•	 Clinical Global Impression of Change (CGIC) score dur-
ing treatment with lidocaine plaster (from 1 “very much 
improved” to 6 “very much worse”)
•	 Occurrence of adverse events
•	 Conclusions of the practitioner
The presence of hyperalgesia (increased pain sensitiv-
ity in response to nociceptive stimuli) and allodynia (pain 
response to nonnociceptive stimuli) was confirmed by the 
treating physician using diagnostic tools of his/her choice. 
Practitioners rated the severity of allodynia on a scale from 
0 = no pain or discomfort to touch, 1 = uncomfortable, but 
tolerable to touch, 2 = painful, to 3 = extremely painful, 
patient cannot stand touching.
Twenty-four pain practitioners from Austria (n = 1), 
  Belgium (4), Croatia (1), France (1), Germany (2), Poland (3), 
Portugal (3), Russia (1), Slovenia (1), Spain (2), United 
Kingdom (4), and Venezuela (1) submitted a total of 89 case 
reports. All reports were tabulated according to indication 
and displayed during the discussion sessions. The original 
report forms were also available for perusal at each session. 
In 17 cases, both etiologies were present; these cases were 
discussed for both indications. All cases were reviewed 
jointly by the group participants and provided a basis for 
the first discussions in the four groups. From this starting 
point, the discussions moved on to an exchange of experi-
ence between the specialists regarding outcome predictors. 
Final conclusions were drawn collectively after the group 
discussions.
Chronic low back pain  
with neuropathic components
The two groups reviewed 41 cases of chronic low back pain 
with neuropathic components. Table 1 summarizes these 
cases across different etiologies and lists them sorted by 
degree of improvement (CGIC score). The 17 cases where 
both etiologies were present (nLBP and PNCCP) are tabu-
lated in Table 2, but baseline data were included in calcula-
tions for both nLBP and PNCCP.
Patients were mainly Caucasian (88%), with a mean 
age of 55.9 ± 15.7 years and a slightly higher proportion of 
females (58.5%). Mean duration of pain was 3.9 ± 5.2 years. 
The majority of patients had received multiple pain medica-
tions during the course of their disease. Lidocaine medicated 
plaster was administered as monotherapy in nine patients 
(22.0%) and in combination with other pain medication in 
32 patients (78.0%).
In 31 (76%) of the reports, patients were judged as 
much or very much improved following treatment with 5% 
lidocaine medicated plaster as determined by the CGIC. 
Minimal improvement was reported for nine patients and “no 
change” was documented in one case. In the group receiv-
ing monotherapy or continuing their previous medication 
in combination with the plaster, ie, the subset of patients in 
which the treatment outcome was most likely related to the 
use of lidocaine plaster, nine patients (69%) experienced 
much or very much improvement and four (31%) showed 
minimal improvement.
Hyperalgesia was more prevalent at baseline in patients 
showing much or very much improvement than in patients 
with minimal or no improvement (81% versus 60%). The 
presence of allodynia was documented for the majority 
of all patients (71%) with no difference when stratified 
by improvement. Severity of allodynia (“painful” or 
“extremely painful”) was comparable in much or very much 
improved patients (45%) to minimally or not improved 
patients (40%). A total of 36% of the patients with much 
or very much improvement had a history of both hyper-
algesia and painful allodynia compared with 20% of the 
patients with no or minimal improvement. Although these 
case reports do not show a clear association between the 
presence of allodynia and a positive treatment outcome, it 
was concluded based on the experience of the practitioners 
that the presence of hyperalgesia and/or allodynia may 
favor a positive treatment outcome using 5% lidocaine 
medicated plaster, in particular if painful allodynia is the 
predominant pain complaint.Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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Table 1 case reports for neuropathic low back pain Table 1 (Continued)
Gender Age Primary diagnosis (pain  
indication/cause of pain)
Localization of  
pain symptoms
Duration of pain  
in years
Hyperalgesia Allodynia/allodynia  
severity rating
Stabbing  
pain
Burning  
pain
Shooting  
pain
Monotherapy Plasters  
per day
Duration of plaster  
treatment (months)
CGIC  
score
F 50 Neuropathic pain, viral  
radiculitis
Periumbilical pain, allodynia 2.0 X 2 X X X Y 1 17
ongoing
1
F 85 Lumbar pain Lumbar 10.0 2–3 X N 1 3 1
F 29 Discopathy Low back pain 0.06 X 0 X Y 1 1.5 1
F 76 Low back pain . facet  
arthrosis
Low back $5.0 X 1 X Y 1 10 1
F 56 Low back pain . facet  
arthrosis
Low back 0.5 X 1 X Y 1 1.5 1
F 58 Lumbosacral syndrome Low back pain, irradiating  
to both thighs; knees
3.0 X 1 X N 1 
3 days; then  
every 3rd day
0.5 2
M 69 Lumbar-sciatic pain Low back pain irradiating  
into lateral and posterior  
part of the right leg
0.17 X 2 X X N 1
3 days; then  
every 3rd day
0.5 2
M 59 Lumbar pain/radiculopathy Lumbar 3.0 X 2 X N 2 1 
ongoing
2
F 43 Lumbar pain/radiculopathy Lumbosacral 2.0 X 2 X N 1 3 2
F 41 sciatica Left leg 0.5 X 1 X X X N 1 3 
ongoing
2
M 50 Low back pain + sciatic pain Low back and left leg ∼ s1 5.0 X 1 X X N 1 1 2
M 45 Neuropathic pain cervical spine, lumbar spine 18.0 X 2 X X X N 1 3 2
M 38 Low back pain . discopathy Low back and left hip 0.17 X 2 X N 1 5 
ongoing
2
F 81 Arthrosis zygapophyseal joint Low back 5.0 2 X X X Y 1 0.75 2
F 44 Arthrosis zygapophyseal joint Low back $5.0 2 X X X N 1 1 2
F 55 Arthrosis zygapophyseal joint +  
sacroiliac joint
Low back pain 0.83 2 X X Y 1 1 2
M 55 low back pain-spondylolisthesis Low back pain 0.33 X NA X X N 1/4 3 2
M 86 low back pain Low back pain 0.17 X NA X N 1/8 
twice a week
1 2
NA 54 Degenerative disc disease Low back pain 1,33 X NA X X N 1/4 
twice a week
2 2
F 50 Lumbar pain Right buttock, scar 0.5 X NA X at right 
buttock
N 2 10 3
M 80 Low back pain Low back 20.0 X 0 X N 1 0.75 3
F 71 sciatic pain bilateral s1 bilateral 10.0 X 0 X X N 2 0.5 3
M 54 Low back pain Low back 1.0 X 0 X X Y 1 1 3
F 62 Lumbosacral syndrome Low back pain irradiating  
into both legs knees  
hands and feet
10.0 X 2 X X N 1 
3 days; then  
every 3rd day
1 3
F 55 Arthrosis zygapophyseal joint Low back $5.0 2 X X Y 1 0.25 3
F 80 Arthrosis zygapophyseal joint Low back left + right $5.0 0 X X N 1 1.5 3
M 68 Lumbar pain Lumbar 7.0 X 3 X X X N 2 3 4
Notes: Allodynia severity rating: 0 = no pain or discomfort to touch, 1 = uncomfortable, but tolerable to touch, 2 = painful, 3 = extremely painful, patient cannot stand 
touching; duration of pain was converted to years, term “many years” was set to $5 years in Table 1 and to 5 years for calculation of means.
Abbreviations: cgic, clinical global impression of change (1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 
6 = very much worse); F, female; M, male; NA, not available; X, symptom present.
The presented case reports showed that patients with 
minimal improvement had a considerably longer duration 
of pain (mean 6.7 years) compared with very much (mean 
4.1 years) and much improved (mean 3.5 years) patients. In 
the opinion of the majority of the physicians, patients with 
a long history of pain are less likely to benefit from lido-
caine plaster and best results are obtained if the treatment is 
initiated early. However, it was conceded that this is appli-
cable to pain medication in general.
Another factor thought to be a positive predictor for treat-
ment with lidocaine plaster is the ability of patients to dif-
ferentiate between back pain and nonback pain components, 
whereas the inability to distinguish between pain locations and 
predominant radicular pain was regarded as a negative   predictor. Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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Table 1 case reports for neuropathic low back pain Table 1 (Continued)
Gender Age Primary diagnosis (pain  
indication/cause of pain)
Localization of  
pain symptoms
Duration of pain  
in years
Hyperalgesia Allodynia/allodynia  
severity rating
Stabbing  
pain
Burning  
pain
Shooting  
pain
Monotherapy Plasters  
per day
Duration of plaster  
treatment (months)
CGIC  
score
F 50 Neuropathic pain, viral  
radiculitis
Periumbilical pain, allodynia 2.0 X 2 X X X Y 1 17
ongoing
1
F 85 Lumbar pain Lumbar 10.0 2–3 X N 1 3 1
F 29 Discopathy Low back pain 0.06 X 0 X Y 1 1.5 1
F 76 Low back pain . facet  
arthrosis
Low back $5.0 X 1 X Y 1 10 1
F 56 Low back pain . facet  
arthrosis
Low back 0.5 X 1 X Y 1 1.5 1
F 58 Lumbosacral syndrome Low back pain, irradiating  
to both thighs; knees
3.0 X 1 X N 1 
3 days; then  
every 3rd day
0.5 2
M 69 Lumbar-sciatic pain Low back pain irradiating  
into lateral and posterior  
part of the right leg
0.17 X 2 X X N 1
3 days; then  
every 3rd day
0.5 2
M 59 Lumbar pain/radiculopathy Lumbar 3.0 X 2 X N 2 1 
ongoing
2
F 43 Lumbar pain/radiculopathy Lumbosacral 2.0 X 2 X N 1 3 2
F 41 sciatica Left leg 0.5 X 1 X X X N 1 3 
ongoing
2
M 50 Low back pain + sciatic pain Low back and left leg ∼ s1 5.0 X 1 X X N 1 1 2
M 45 Neuropathic pain cervical spine, lumbar spine 18.0 X 2 X X X N 1 3 2
M 38 Low back pain . discopathy Low back and left hip 0.17 X 2 X N 1 5 
ongoing
2
F 81 Arthrosis zygapophyseal joint Low back 5.0 2 X X X Y 1 0.75 2
F 44 Arthrosis zygapophyseal joint Low back $5.0 2 X X X N 1 1 2
F 55 Arthrosis zygapophyseal joint +  
sacroiliac joint
Low back pain 0.83 2 X X Y 1 1 2
M 55 low back pain-spondylolisthesis Low back pain 0.33 X NA X X N 1/4 3 2
M 86 low back pain Low back pain 0.17 X NA X N 1/8 
twice a week
1 2
NA 54 Degenerative disc disease Low back pain 1,33 X NA X X N 1/4 
twice a week
2 2
F 50 Lumbar pain Right buttock, scar 0.5 X NA X at right 
buttock
N 2 10 3
M 80 Low back pain Low back 20.0 X 0 X N 1 0.75 3
F 71 sciatic pain bilateral s1 bilateral 10.0 X 0 X X N 2 0.5 3
M 54 Low back pain Low back 1.0 X 0 X X Y 1 1 3
F 62 Lumbosacral syndrome Low back pain irradiating  
into both legs knees  
hands and feet
10.0 X 2 X X N 1 
3 days; then  
every 3rd day
1 3
F 55 Arthrosis zygapophyseal joint Low back $5.0 2 X X Y 1 0.25 3
F 80 Arthrosis zygapophyseal joint Low back left + right $5.0 0 X X N 1 1.5 3
M 68 Lumbar pain Lumbar 7.0 X 3 X X X N 2 3 4
Notes: Allodynia severity rating: 0 = no pain or discomfort to touch, 1 = uncomfortable, but tolerable to touch, 2 = painful, 3 = extremely painful, patient cannot stand 
touching; duration of pain was converted to years, term “many years” was set to $5 years in Table 1 and to 5 years for calculation of means.
Abbreviations: cgic, clinical global impression of change (1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 
6 = very much worse); F, female; M, male; NA, not available; X, symptom present.
Diagnosis and site of pain were considered to have no predictive 
value. Also, the description of neuropathic pain quality as given 
in the case reports (eg, burning, stabbing, shooting) was judged 
as not reliable enough for the   prediction of treatment outcome, 
although clustering of the case reports by primary diagnosis 
revealed that, for instance, seven of eight patients presenting 
with failed back surgery   syndrome reported   clinical symptoms 
of burning pain (with and without hyperalgesia and/or allo-
dynia), only one reported stabbing pain, and seven of those 
patients showed much or very much improvement (minimal 
improvement in the remaining one patient). Overall, two-thirds 
of the patients with nLBP (68.3%) reported burning pain, but no 
clear relationship between this symptom and clinical outcome 
was seen. However, this analysis of the case reports was not in Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
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Table 2 case reports for neuropathic low back pain after surgical trauma Table 2 (Continued)
Gender Age Primary diagnosis 
(pain indication/cause 
of pain)
Localization 
of pain symptoms
Duration 
of pain in years
Hyperalgesia Allodynia/allodynia 
severity rating
Stabbing 
pain
Burning 
pain
Shooting 
pain
Monotherapy Plasters per day Duration of plaster 
treatment (months)
CGIC score
F 75 Failed back surgery syndrome: laminectomy 
L4–L5 + decompression and fusion with 
supplemental instrumentation – Nov 2008; 
2nd surgery 24 hours after the 1st one – pain 
and right foot dorsiflexion paresis
lumbar back pain and right leg 
paresthesias and dysesthesias
0.58 X 2 X N 1 6 
ongoing
1 – on the 
back
F 49 Failed back surgery syndrome focal 
neuropathic back pain
back, around the postoperative scar 0.33 X 1 X Y 1 1 1
M 22 Low back pain after lumbar puncture 
for spinal anesthesia (for circumcision)a
axial pain in the point of puncture 
and nearby L3–L4
0.17 X 1 X N 1/4 2 1
M 69 TURP Feb 1990 failed back surgery syndrome – 
spine surgery (1992) to perform drainage of 
spine epidural empyema in the context of conn 
syndrome (saddle anesthesia, bladder and bowel 
dysfunction)
lumbar pain, around incision scar 18.0 X 2–3 X X N 1 8 
ongoing
1
F 52 Failed back surgery syndrome back 5.0 1 X N 1 5 
ongoing
2
F 67 Fracture L1, traffic accident; spine surgery 
April 2004; 2006: 2nd spine surgery for material 
extraction
low back pain, incidental, like 
stabbing; since second surgery. 
without irradiation
3.0 X 0 X N 1 6 
ongoing
2
M 63 Lumbar pain/postsurgical, lumbar pain L4–L5 lumbar (scar) + neuropathic pain 
right lower limb
0.33 X X X N 1 1/2 10 2
M 35 Postlaminectomy L5–s1 and surgery for lumbar 
herniated disc L4–L5
left foot 0.08 X 2 X X N 1 3 2
F 35 Neck pain post failed surgery, nociceptive 
and neuropathic pain
cervicobrachial 
left area
2.0 X 2 X N 1 3 2
F 44 Failed back surgery syndrome low back 1.0 1 X N 1 2 2
M 49 Failed back surgery low back 3.0 X 0 X N 1 3 2
F 36 Failed back surgery syndrome low back pain 2.0 X 0 X N 1/4 3 2
F 82 Failed back surgery syndrome back and right buttock 0.5 X 0 X X N 1 1.5 3
M 52 Failed back surgery lumbar spine 5.0 1 X X N 1 1/2 1.5 3
F 48 Failed back surgery syndrome low back, left leg 4.0 2 X X N 2 0.75 3
M 39 Failed back surgery back and left part 
of low back
3.0 X 0 X X N 1 0.5 5–6
F 43 Painful surgery (NR) NR 0.5 X 3 N 1 7 
ongoing
NA
Notes: aParesthesias and dysesthesias. Allodynia severity rating: 0 = no pain or discomfort to touch, 1 = uncomfortable, but tolerable to touch, 2 = painful, 3 = extremely painful, 
patient cannot stand touching; duration of pain was converted to years, term “many years” was set to $5 years in the table and to 5 years for calculation of means.
Abbreviations: cgic, clinical global impression of change (1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 
6 = very much worse); F, female; M, male; NA, not available; NR, not readable; TURP, transurethral resection of prostate; X, symptom present.
agreement with the general experience of the participants, who 
considered burning, stabbing, and shooting pain as predictors 
of treatment success with 5% lidocaine medicated plaster.
Treatment with the lidocaine plaster led to much improve-
ment in a 35-year-old male patient presenting with pain in 
his left foot following laminectomy at L5-S1 and surgery 
for a herniated disc at L4–L5. The patient initially presented 
with hyperalgesia, painful allodynia, and burning and stab-
bing pain with an average intensity of 9 out of 10 on a visual 
analog scale (VAS). Physical examination and diagnostic 
tests revealed reduced strength due to pain, pain during 
walking, and superficial sensitivity, ie, diffuse hypoesthesia 
in the left inferior limb and reduced patellar reflexes. The 
patient received three months of add-on treatment with one 
lidocaine plaster every 12 hours on the lateral side of the 
affected foot (with concomitant tramadol, 5 to 8 drops orally, 
corresponding to 12.5–20 mg every eight hours). At the end 
of the lidocaine plaster treatment, the patient showed much 
improvement, with occasional pain if a shoe was too tight or 
if he walked long distances.
Very much improvement in pain following lidocaine 
plaster monotherapy was reported for a 50-year-old female 
patient with localized, periumbilical, neuropathic pain (viral 
radiculitis) with an average intensity of 6 to 8 out of 10 on a 
VAS scale. The patient presented with hyperalgesia, painful 
allodynia, stabbing, burning, and shooting pain which had Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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Table 2 case reports for neuropathic low back pain after surgical trauma Table 2 (Continued)
Gender Age Primary diagnosis 
(pain indication/cause 
of pain)
Localization 
of pain symptoms
Duration 
of pain in years
Hyperalgesia Allodynia/allodynia 
severity rating
Stabbing 
pain
Burning 
pain
Shooting 
pain
Monotherapy Plasters per day Duration of plaster 
treatment (months)
CGIC score
F 75 Failed back surgery syndrome: laminectomy 
L4–L5 + decompression and fusion with 
supplemental instrumentation – Nov 2008; 
2nd surgery 24 hours after the 1st one – pain 
and right foot dorsiflexion paresis
lumbar back pain and right leg 
paresthesias and dysesthesias
0.58 X 2 X N 1 6 
ongoing
1 – on the 
back
F 49 Failed back surgery syndrome focal 
neuropathic back pain
back, around the postoperative scar 0.33 X 1 X Y 1 1 1
M 22 Low back pain after lumbar puncture 
for spinal anesthesia (for circumcision)a
axial pain in the point of puncture 
and nearby L3–L4
0.17 X 1 X N 1/4 2 1
M 69 TURP Feb 1990 failed back surgery syndrome – 
spine surgery (1992) to perform drainage of 
spine epidural empyema in the context of conn 
syndrome (saddle anesthesia, bladder and bowel 
dysfunction)
lumbar pain, around incision scar 18.0 X 2–3 X X N 1 8 
ongoing
1
F 52 Failed back surgery syndrome back 5.0 1 X N 1 5 
ongoing
2
F 67 Fracture L1, traffic accident; spine surgery 
April 2004; 2006: 2nd spine surgery for material 
extraction
low back pain, incidental, like 
stabbing; since second surgery. 
without irradiation
3.0 X 0 X N 1 6 
ongoing
2
M 63 Lumbar pain/postsurgical, lumbar pain L4–L5 lumbar (scar) + neuropathic pain 
right lower limb
0.33 X X X N 1 1/2 10 2
M 35 Postlaminectomy L5–s1 and surgery for lumbar 
herniated disc L4–L5
left foot 0.08 X 2 X X N 1 3 2
F 35 Neck pain post failed surgery, nociceptive 
and neuropathic pain
cervicobrachial 
left area
2.0 X 2 X N 1 3 2
F 44 Failed back surgery syndrome low back 1.0 1 X N 1 2 2
M 49 Failed back surgery low back 3.0 X 0 X N 1 3 2
F 36 Failed back surgery syndrome low back pain 2.0 X 0 X N 1/4 3 2
F 82 Failed back surgery syndrome back and right buttock 0.5 X 0 X X N 1 1.5 3
M 52 Failed back surgery lumbar spine 5.0 1 X X N 1 1/2 1.5 3
F 48 Failed back surgery syndrome low back, left leg 4.0 2 X X N 2 0.75 3
M 39 Failed back surgery back and left part 
of low back
3.0 X 0 X X N 1 0.5 5–6
F 43 Painful surgery (NR) NR 0.5 X 3 N 1 7 
ongoing
NA
Notes: aParesthesias and dysesthesias. Allodynia severity rating: 0 = no pain or discomfort to touch, 1 = uncomfortable, but tolerable to touch, 2 = painful, 3 = extremely painful, 
patient cannot stand touching; duration of pain was converted to years, term “many years” was set to $5 years in the table and to 5 years for calculation of means.
Abbreviations: cgic, clinical global impression of change (1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 
6 = very much worse); F, female; M, male; NA, not available; NR, not readable; TURP, transurethral resection of prostate; X, symptom present.
lasted for two years prior to initiation of lidocaine plaster 
treatment.
Unsatisfactory treatment with lidocaine plaster was 
reported for a 62-year-old polymorbid male patient (dia-
betes, polyneuropathy, hypothyreosis, high blood pressure, 
psoriatic arthritis) with a diagnosis of lumbosacral syndrome 
and low back pain radiating into both legs, knees, hands, and 
feet (10 out of 10 on a VAS scale). He had been in pain for 
10 years, with hyperalgesia, painful allodynia, and stabbing 
and burning pain symptoms. He improved minimally when 
lidocaine therapy was added to his pre-existing medications 
(nonsteroidal anti-inflammatory drugs and a combination of 
a weak opioid and paracetamol).
While most clinical experience of the lidocaine plaster 
is with neuropathic pain, one of the nLBP groups felt that 
patients with structural abnormalities of the spinal cord, even 
though the cause has usually been characterized as nocicep-
tive, may respond to topical treatment with lidocaine and that 
this should be explored in the future.
Chronic neuropathic pain after 
surgical and nonsurgical trauma
Fifty-eight case reports with a diagnosis of PNCCP were 
submitted (51.7% male, mean age 50.1 ± 15.5 years, mean 
duration of pain 2.6 ± 4.5 years, Table 3). The 17 cases Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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Table 3 case reports for neuropathic pain after surgical and nonsurgical trauma Table 3 (Continued)
Gender Age Primary diagnosis  
(pain indication/cause of pain)
Localization of pain symptoms Duration of  
pain in years
Hyperalgesia Allodynia/allodynia  
severity rating
Stabbing  
pain
Burning  
pain
Shooting  
pain
Monotherapy Plasters  
per day
Duration of plaster  
treatment (months)
CGIC score
F 54 Longstanding low back pain and  
left knee pain post TKRa
Left knee 0.17 1 Y 3 4 1
F 65 After knee surgery 7 years ago Right knee, infrapatellar nerve 6.0 X 2–3 X X N NA 12 1
F 30 Tibial fracture and osteosynthesis anterior aspect of the skin (scar area) 0.5 1 X X N 1/2 2 1
F 46 Post-traumatic neuropathic pain  
(dog attack)
severe pain in the right lower calf +  
ankle on all weight bearing activities
1.5 X 3 X X X N 1 1/2 18 1
M 55 Breast cancer; staging iiA, T2N0M0,  
status after right mastectomy (1 m),  
postmastectomy (postsurgery)  
painful syndrome
severe shooting pain in the right  
hand, burning pain upon the light  
touch in the region under the  
postoperative scar
0.08 X 3 X X N 3 0.5 
then occasionally  
for 2 months
1
F 18 scar neuralgia postfracture Forearm 2.0 X 2 X Y 1/2 1 1
M 43 Neuropathic painb left inguinal region 1.67 X 2 X X X N 1 27
ongoing
1
M 41 Renal malignant tumor surgery,  
acute neuropathic pain
postoperative wound 0.02 X 3 X X X Y 1 0.25 1
M 69 Persistent postoperative pain  
post-thoracotomy
right side of chest wall 0.33 2 X X N 1/2 2 1
M 45 inguinal neuralgia posthernia repair groin 0.25 X 3 X X Y 2 6 1
F 31 Post-traumatic right knee pain Right anterior knee 1.33 X 2 X Y 2 1.5 2
F 41 complex regional pain  
syndrome ii, and wrist NR
Back of right hand and medial aspect 2.5 X 2 X Y 1; 2–3 days in  
the evening
9 2
M 59 Neuropathic postsurgical  
(TKR) knee pain
Right anterior knee 2.0 X 3 X X N 2 2 2
M 82 sarcoma of soft tissues of right  
gluteus region, staging T2N1MX.  
A severe somatic painful syndrome  
with neuropathic component.
severe pain in the right gluteus  
region, shooting pain in the right  
leg from the hip to the foot,  
burning pain at the median surface  
of the right hip
0.17 X 2 X X X N 2 1 2
F 57 Thoracic pain after 2 thoracotomies  
(Aug and sept 2008), pulmonary  
empyema (right lung)c
permanent and persistent thoracalgia,  
very severe; level T7 and T8, on the  
right side; Persistent pain at rectus  
supraumbilical muscle
0.58 X 3 X X X N 1 8
ongoing
2g
3h
F 42 Postoperative pain after breast  
reconstruction
back 0.5 X 2 X N 1 1/2 NA 2
F 46 Poststernotomy painful keloid scar of sternotomy 3.0 1 X N 1 1 2
F 80 Postknee replacement pain knee (anterior) 0.5 2 X X N 1 14 2
F 58 Reflected ligament fracture, then  
acute median nerve compression  
requiring surgery; complex regional  
pain syndrome (neuropathic)
intolerant of shower/light  
clothing over upper chest wall
2.0 X 3 X N 2 15 2
M 56 Post-thoracotomy pain area of the thoracic surgery 0.25 2 X N 1 8 2
M 64 Phantom pain left stump of lower leg 23.0 X 2 X N 1 15
ongoing
2
M 42 Pain in the chest, status  
postoperative neuropathic pain
Right costal arch 2.0 X 2 X X X N 1 15
ongoing
2
M 55 Neuropathy of the left mental nerve  
after excision of tumor of mandible
left side of the chin 1.0 X 2 X Y 1/4 2 2
M 24 inguinal neuralgia posthernia repair groin 0.75 X 0 X X Y 1 NA 2
M 48 Lumbar disc herniation surgery external aspect of left thigh and leg 1.0 1 X X N 1/2 2 2
M 38 Postsurgical painful scar after  
elbow surgery
left elbow 3.0 2 X Y 1/2 7 2
M 64 intercostal painful neuropathy  
(post-traumatic)
dermatome right side .20.0 X 3 X N 1/2 5 2
M 65 Postherniorrhaphy pain inguinal/groin area 1.5 X 3 X X X N 1 20 2
M 29 Testicular neuralgia left testis 0.25 3 X X X N 2 3 2 
3
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Table 3 case reports for neuropathic pain after surgical and nonsurgical trauma Table 3 (Continued)
Gender Age Primary diagnosis  
(pain indication/cause of pain)
Localization of pain symptoms Duration of  
pain in years
Hyperalgesia Allodynia/allodynia  
severity rating
Stabbing  
pain
Burning  
pain
Shooting  
pain
Monotherapy Plasters  
per day
Duration of plaster  
treatment (months)
CGIC score
F 54 Longstanding low back pain and  
left knee pain post TKRa
Left knee 0.17 1 Y 3 4 1
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F 30 Tibial fracture and osteosynthesis anterior aspect of the skin (scar area) 0.5 1 X X N 1/2 2 1
F 46 Post-traumatic neuropathic pain  
(dog attack)
severe pain in the right lower calf +  
ankle on all weight bearing activities
1.5 X 3 X X X N 1 1/2 18 1
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status after right mastectomy (1 m),  
postmastectomy (postsurgery)  
painful syndrome
severe shooting pain in the right  
hand, burning pain upon the light  
touch in the region under the  
postoperative scar
0.08 X 3 X X N 3 0.5 
then occasionally  
for 2 months
1
F 18 scar neuralgia postfracture Forearm 2.0 X 2 X Y 1/2 1 1
M 43 Neuropathic painb left inguinal region 1.67 X 2 X X X N 1 27
ongoing
1
M 41 Renal malignant tumor surgery,  
acute neuropathic pain
postoperative wound 0.02 X 3 X X X Y 1 0.25 1
M 69 Persistent postoperative pain  
post-thoracotomy
right side of chest wall 0.33 2 X X N 1/2 2 1
M 45 inguinal neuralgia posthernia repair groin 0.25 X 3 X X Y 2 6 1
F 31 Post-traumatic right knee pain Right anterior knee 1.33 X 2 X Y 2 1.5 2
F 41 complex regional pain  
syndrome ii, and wrist NR
Back of right hand and medial aspect 2.5 X 2 X Y 1; 2–3 days in  
the evening
9 2
M 59 Neuropathic postsurgical  
(TKR) knee pain
Right anterior knee 2.0 X 3 X X N 2 2 2
M 82 sarcoma of soft tissues of right  
gluteus region, staging T2N1MX.  
A severe somatic painful syndrome  
with neuropathic component.
severe pain in the right gluteus  
region, shooting pain in the right  
leg from the hip to the foot,  
burning pain at the median surface  
of the right hip
0.17 X 2 X X X N 2 1 2
F 57 Thoracic pain after 2 thoracotomies  
(Aug and sept 2008), pulmonary  
empyema (right lung)c
permanent and persistent thoracalgia,  
very severe; level T7 and T8, on the  
right side; Persistent pain at rectus  
supraumbilical muscle
0.58 X 3 X X X N 1 8
ongoing
2g
3h
F 42 Postoperative pain after breast  
reconstruction
back 0.5 X 2 X N 1 1/2 NA 2
F 46 Poststernotomy painful keloid scar of sternotomy 3.0 1 X N 1 1 2
F 80 Postknee replacement pain knee (anterior) 0.5 2 X X N 1 14 2
F 58 Reflected ligament fracture, then  
acute median nerve compression  
requiring surgery; complex regional  
pain syndrome (neuropathic)
intolerant of shower/light  
clothing over upper chest wall
2.0 X 3 X N 2 15 2
M 56 Post-thoracotomy pain area of the thoracic surgery 0.25 2 X N 1 8 2
M 64 Phantom pain left stump of lower leg 23.0 X 2 X N 1 15
ongoing
2
M 42 Pain in the chest, status  
postoperative neuropathic pain
Right costal arch 2.0 X 2 X X X N 1 15
ongoing
2
M 55 Neuropathy of the left mental nerve  
after excision of tumor of mandible
left side of the chin 1.0 X 2 X Y 1/4 2 2
M 24 inguinal neuralgia posthernia repair groin 0.75 X 0 X X Y 1 NA 2
M 48 Lumbar disc herniation surgery external aspect of left thigh and leg 1.0 1 X X N 1/2 2 2
M 38 Postsurgical painful scar after  
elbow surgery
left elbow 3.0 2 X Y 1/2 7 2
M 64 intercostal painful neuropathy  
(post-traumatic)
dermatome right side .20.0 X 3 X N 1/2 5 2
M 65 Postherniorrhaphy pain inguinal/groin area 1.5 X 3 X X X N 1 20 2
M 29 Testicular neuralgia left testis 0.25 3 X X X N 2 3 2 
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Table 3 (Continued) Table 3 (Continued)
Gender Age Primary diagnosis  
(pain indication/ cause of pain)
Localization of pain symptoms Duration of  
pain in years
Hyperalgesia Allodynia/allodynia  
severity rating
Stabbing  
pain
Burning  
pain
Shooting  
pain
Monotherapy Plasters  
per day
Duration of plaster  
treatment (months)
CGIC score
M 36 scar pain after inguinal hernia repair inguinal hernia region 0.33 X 0 N 1/8 
twice a week
2 2
F 55 Postoperative pain after  
popliteal artery stentingd
Anterior aspect of the skin 2.0 2 X N 1/2 10
ongoing
2
F 68 Left TKR postsurgical knee paine Left anterior knee 3.0 X X X N 2 1 3
M 31 Neuropathy after inguinal hernia  
operation
Left and right inguinal region 6.0 X 2 X N 1/2 1 3
F 32 Post-traumatic pain in the right wrist in the lateral external port  
of the right wrist
1.5 X 3 X N 1 12 3
F 69 Neuropathic pain over right  
knee failing TKR
Periarticular, right knee 0.5 2 X X X N 1 NA 3
F 36 Pain inguinal after operation  
of hernia
Left inguinal region 0.25 0 X X N 1 8
ongoing
3
F 72 Trigeminal pain after ear operation V1 2.0 X 0 N 1/2 3 3
M 65 Postherniorrhaphy inguinal right Area of the surgery (right inguinal) 1.0 X 2 X N 1 1 3
M 52 Postoperative foot pain (inguinal  
hernia repair)f
internal side of right big toe 0.15 2 X N 1/8 1 3
M 44 complex regional pain syndrome ii – 
postamputation
stump of the right thumb 5.0 3 X N 1/8 1 4
M 40 Right inguinal hernia repair scar and inguinal area 2.0 1 X X N 1/2 1 4
Notes: aWeird; bparesthesia; cparesthesias and dysesthesias; dpins and needles; esharp saw like; fnumbness; gfrom 15 April 2009 until October 2009; hafter October 2009. 
Allodynia severity rating: 0 = no pain or discomfort to touch, 1 = uncomfortable, but tolerable to touch, 2 = painful, 3 = extremely painful, patient cannot stand touching; 
duration of pain was converted to years, term “many years” was set to $5 years in the table and to 5 years for calculation of means.
Abbreviations: cgic, clinical global impression of change (1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 
6 = very much worse); F, female; M, male; NA, not available; NR, not readable; TKR, total knee replacement; X, symptom present.
with both etiologies present (Table 2) were included in the 
calculations of baseline data.
The majority of patients (83%) received lidocaine plaster 
as add-on therapy. Seventy-six percent of all patients showed 
much or very much improvement (as rated on the CGIC) 
during treatment with 5% lidocaine medicated plaster. The 
10 patients (17%) receiving monotherapy were all very much 
or much improved.
Similar to the nLBP cases, the presence of hyperalgesia 
was clearly associated with a better treatment outcome and 
considered to have some predictive value. Of the patients 
showing much or very much improvement on the CGIC, 75% 
had initially experienced hyperalgesia compared with 46% 
of patients with minimal or no improvement. The presence 
of allodynia was documented for the vast majority (81%) 
of patients; 66% of much or very much improved patients 
had initially presented with “painful” or “extremely painful” 
allodynia compared with 54% of patients with minimal or 
no improvement. From the submitted case reports, no clear 
association between the occurrence of allodynia, duration of 
pain, or pain quality (burning, shooting, stabbing, or other), 
and treatment response was apparent. There was also no 
obvious impact of diagnosis or site of pain on treatment out-
come. Nevertheless, based on general treatment experience 
shared in the discussion groups, patients with allodynia, 
hyperalgesia, and spontaneous pain like burning or shooting 
were felt to be good candidates for treatment with lidocaine 
plaster. Long-lasting pain was thought to be associated with a 
negative treatment outcome by some of the physicians. Local-
ized pain as opposed to widespread or generalized pain and 
positive sensory symptoms, like dysesthesias, were clearly 
identified as predictors for treatment with lidocaine plaster, 
whereas spontaneous pain without evoked pain and negative 
sensory symptoms, such as anesthesias or hypoesthesias, 
were considered linked with negative treatment outcomes. 
No predictive value was associated with paresthesia.
Superficial spontaneous (nonevoked) pain was considered 
to be a positive predictor as opposed to deep or widespread 
pain for treatment with lidocaine plaster. A 19-year-old 
male with spinal dystonia who received an abdominal neu-
romodulator implant developed superficial scar pain after 
surgery, including tactile allodynia (rated 7–10 on a VAS 
scale). Lidocaine plaster treatment resulted in satisfactory 
pain relief. A 51-year-old female with bipolar disorder who 
received a neuromodulator implant in the thorax experienced 
deep pain after surgery, perhaps generated by deeper nerve 
trauma and an inflammatory seroma. In contrast with the first 
case, she did not benefit from lidocaine plaster.Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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Table 3 (Continued) Table 3 (Continued)
Gender Age Primary diagnosis  
(pain indication/ cause of pain)
Localization of pain symptoms Duration of  
pain in years
Hyperalgesia Allodynia/allodynia  
severity rating
Stabbing  
pain
Burning  
pain
Shooting  
pain
Monotherapy Plasters  
per day
Duration of plaster  
treatment (months)
CGIC score
M 36 scar pain after inguinal hernia repair inguinal hernia region 0.33 X 0 N 1/8 
twice a week
2 2
F 55 Postoperative pain after  
popliteal artery stentingd
Anterior aspect of the skin 2.0 2 X N 1/2 10
ongoing
2
F 68 Left TKR postsurgical knee paine Left anterior knee 3.0 X X X N 2 1 3
M 31 Neuropathy after inguinal hernia  
operation
Left and right inguinal region 6.0 X 2 X N 1/2 1 3
F 32 Post-traumatic pain in the right wrist in the lateral external port  
of the right wrist
1.5 X 3 X N 1 12 3
F 69 Neuropathic pain over right  
knee failing TKR
Periarticular, right knee 0.5 2 X X X N 1 NA 3
F 36 Pain inguinal after operation  
of hernia
Left inguinal region 0.25 0 X X N 1 8
ongoing
3
F 72 Trigeminal pain after ear operation V1 2.0 X 0 N 1/2 3 3
M 65 Postherniorrhaphy inguinal right Area of the surgery (right inguinal) 1.0 X 2 X N 1 1 3
M 52 Postoperative foot pain (inguinal  
hernia repair)f
internal side of right big toe 0.15 2 X N 1/8 1 3
M 44 complex regional pain syndrome ii – 
postamputation
stump of the right thumb 5.0 3 X N 1/8 1 4
M 40 Right inguinal hernia repair scar and inguinal area 2.0 1 X X N 1/2 1 4
Notes: aWeird; bparesthesia; cparesthesias and dysesthesias; dpins and needles; esharp saw like; fnumbness; gfrom 15 April 2009 until October 2009; hafter October 2009. 
Allodynia severity rating: 0 = no pain or discomfort to touch, 1 = uncomfortable, but tolerable to touch, 2 = painful, 3 = extremely painful, patient cannot stand touching; 
duration of pain was converted to years, term “many years” was set to $5 years in the table and to 5 years for calculation of means.
Abbreviations: cgic, clinical global impression of change (1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 
6 = very much worse); F, female; M, male; NA, not available; NR, not readable; TKR, total knee replacement; X, symptom present.
Chronic neuropathic back pain  
after surgical trauma
Seventeen case reports with a diagnosis of both PNCCP and 
nLBP were submitted and discussed in the nLBP and the 
PNCCP groups (41.2% male, mean age 50.6 ± 16.0 years 
(Table 2). Although the mean duration of pain was 
2.9 ± 4.2 years, one patient had an exceptionally long duration 
of pain of 18 years, giving a mean pain duration in the group 
of 1.9 ± 1.7 years without inclusion of this outlier.
All except for one patient received lidocaine plaster as 
an add-on to pre-existing pain medication, and 76% of the 
patients showed much or very much improvement (as rated 
on the CGIC) during treatment with 5% lidocaine medicated 
plaster. The one patient receiving monotherapy was very 
much improved.
The majority of patients presented with hyperalgesia 
(76%) and allodynia (64%). Burning, shooting, or stabbing 
pain were experienced by 71%, 47%, and 35%, respectively. 
The patient with an exceptionally long duration of pain 
(18 years) was a particularly interesting case. This 69-year-old 
male underwent two surgical procedures in the early 1990s 
(transurethral resection of prostate and drainage of a spinal 
epidural empyema in the context of Conn syndrome (blad-
der and bowel dysfunction, failed back   surgery syndrome). 
  His average pain score on the NRS prior to initiation of lido-
caine plaster treatment was 8–9, with a maximum of 10, and 
he presented with hyperalgesia, painful to extremely painful 
allodynia, lumbar pain around the incision scar, and shooting 
pain triggered by pressure, anesthesia at S4–S5, hypoesthesia 
at S3, and pelvic paresthesia. His pre-existing regimen of 
trimetazidine, furadantine, lansoprazole, chlordiazepoxide-
clidinium bromide, and naproxen as required was stopped, 
and treatment with capsaicin, pregabalin, amitriptyline, 
tramadol, and lidocaine plaster was initiated. One month 
after the start of this regimen, pregabalin, amitriptyline, and 
tramadol were stopped due to the occurrence of adverse 
events, and pain has since been successfully controlled (very 
much improved) by capsaicin and lidocaine plaster.
Eighteen adverse events in 11 patients were reported on 
the 89 case report forms submitted. Mild application site 
reactions were the most common (six patients) and were 
considered likely related to lidocaine plaster treatment in five 
patients. Further adverse events were nausea (n = 2),   vomiting 
(n = 1), somnolence (n = 1), and dizziness (n = 1). One patient 
had moderate diarrhea and severe vertigo, and one presented 
with severe depression, anxiety, suicide ideation, and worsen-
ing of pain. Except for an unclear relationship for “dizziness” 
and no available assessment for the patient with somnolence Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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and nausea, none of the other adverse events were considered 
to be related to lidocaine plaster treatment. Three patients 
discontinued owing to adverse events (two application site 
reactions, one episode of dizziness).
Summary
Discussions in the four groups achieved similar conclusions 
regarding positive and negative outcome predictors for the 
treatment of nLBP and PNCCP with 5% lidocaine medicated 
plaster (Table 4).
There was general agreement that hyperalgesia and/or 
allodynia and localized pain, as opposed to widespread or 
generalized pain, are predictive of treatment success in both 
indications. Pain quality (ie, burning, stabbing, shooting) was 
judged to be a positive predictor for PNCCP and nLBP after 
surgical trauma, but the physicians felt it was not reliable 
enough for the prediction of treatment outcome for nLBP. 
Besides hyperalgesia and allodynia, other positive sensory 
phenomena, such as dysesthesia, were linked to treatment 
success, whereas negative sensory phenomena, such as 
anesthesia and hypoesthesia, were assessed to be associated 
with poorer outcomes. Paresthesia and diagnosis/site of pain 
were considered to be of no predictive value.
The case reports discussed at the meeting were contrib-
uted at the discretion of each physician, which introduces a 
possible selection bias, in that they are not necessarily repre-
sentative of the entire treated population, but may allow a first 
assessment of the drug’s effectiveness in various neuropathic 
low back pain and post-traumatic pain conditions.
In all discussion groups, the clinical experience of par-
ticipants clearly pointed to allodynia as a major positive 
predictor of treatment success with the plaster for the two 
indications. Previous case reports showing improvement 
of allodynia in patients with chronic low back pain15 and 
PNCCP11,12 using lidocaine plaster as an adjunct to exist-
ing pain therapy support the findings. The identification of 
allodynia as one potential predictor for treatment success in 
nLBP and PNCCP is consistent with treatment experience 
in other indications. Several randomized controlled trials 
have shown clinically relevant effects on the reduction of 
allodynia in patients with postherpetic neuralgia and other 
focal peripheral neuropathic pain conditions,3,5,26,27 which 
mirrors the clinical experience of participants at the previ-
ous two meetings in Athens (2007) and Berlin (2008). They 
considered allodynia and hyperalgesia as positive predictors 
for treatment success in postherpetic neuralgia, diabetic 
polyneuropathy, trigeminal neuralgia, and complex regional 
pain syndrome. Because different neuropathic pain condi-
tions share common symptoms, the experts summarized their 
overall experience with 5% lidocaine medicated plaster dur-
ing their final discussion and ranked potential predictors on 
the basis of published evidence and their own experience in 
different indications as proposing relatively high, medium, 
or low treatment success (Table 5).
This led to the hypothesis that the value of predictors 
combined with an indication might indicate the likelihood 
of success. Furthermore, it was generally agreed by the 
participating clinicians that this symptom-based approach 
is preferable to an indication-based approach when select-
ing pain medication. The view that the classical indica-
tion/disease-based treatment approach might have to be 
reconsidered is echoed in recent publications28,29 and a lot 
Table 4 Potential predictors for treatment success with 5% lidocaine medicated plaster
Predictive value Chronic low back pain 
with neuropathic components
Chronic neuropathic pain after 
surgical and nonsurgical trauma
Positive Localized pain
hyperalgesia
Allodynia
Differentiation between back 
pain and nonback pain
Localized pain
hyperalgesia
Allodynia
Superficial pain
Pain quality
Positive sensory symptoms (eg, dysesthesia)
Negative Long duration of paina
Predominant radicular pain
Widespread pain
Long duration of paina
spontaneous pain without evoked pain
Deep pain
Widespread pain
Negative sensory symptoms 
(eg, anesthesia, hypoesthesia)
Uncertain Pain quality
No value Diagnosis of pain
site of pain
Diagnosis of pain
site of pain 
Paresthesia
Notes: Pain quality = burning, shooting, stabbing, or other descriptors of pain. aPain of long duration is difficult to treat with any pain medication.Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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of effort have been made to classify patients on the basis 
of their somatosensory profile, with the ultimate goal of 
finding new treatment approaches for chronic neuropathic 
pain, focusing on symptoms, signs, and pathophysiologic 
mechanisms rather than on underlying disease alone.30,31 In 
addition, there is an urgent need to accumulate clinical data 
which, in turn, could help to determine therapeutic outcomes 
and criteria that a novel analgesic drug should meet in order 
to be a clinically worthwhile drug.
Some further general observations for treatment success 
with lidocaine plaster included a crucial requirement for 
clinical examination with a possible diagnosis of neuropathic 
pain. However, it was generally agreed by the participants 
from the nLBP groups that a clear definition for neuropathic 
back pain is lacking. Furthermore, early treatment is recom-
mended, in particular with regard to neuropathic PNCCP. 
According to the experience of the participants, healing after 
surgery can take up to six months, so it was suggested that 
lidocaine plaster treatment should be initiated 1–2 weeks 
following surgery in order to prevent pain from becoming 
chronic. Patients with a long duration of pain are difficult to 
treat with any analgesic, and the lidocaine plaster is likely 
to be used as add-on therapy because it would be impossible 
to stop existing systemic treatment in most cases (although 
decreased dosing of these concomitant medications is often 
possible). However, an analysis of the case report data 
concerning a potential relationship between pain duration 
and treatment outcome did not show a trend towards a more 
favorable treatment effect in patients with a short duration 
of pain. Motivation and realistic expectations of the patients 
were also regarded as a prerequisite to treatment success. 
Furthermore, many participants commented that patients 
with psychologic problems are generally difficult to treat 
with any analgesic.
In summary, the findings of this conference have iden-
tified several predictors for treatment success with 5% 
lidocaine medicated plaster in the indications of chronic 
nLBP and neuropathic PNCCP. Common symptomatology 
with other neurologic indications suggests that treatment 
of localized neuropathic pain symptoms with the plas-
ter can be considered across different neuropathic pain 
indications.
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